These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 26575306)

  • 1. Cardiovascular Risk in Primary Hyperaldosteronism.
    Prejbisz A; Warchoł-Celińska E; Lenders JW; Januszewicz A
    Horm Metab Res; 2015 Dec; 47(13):973-80. PubMed ID: 26575306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular outcomes in patients with primary aldosteronism after treatment.
    Catena C; Colussi G; Nadalini E; Chiuch A; Baroselli S; Lapenna R; Sechi LA
    Arch Intern Med; 2008 Jan; 168(1):80-5. PubMed ID: 18195199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comorbidities in primary aldosteronism.
    Quinkler M; Born-Frontsberg E; Fourkiotis VG
    Horm Metab Res; 2010 Jun; 42(6):429-34. PubMed ID: 20049673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Salt Appetite and its Effects on Cardiovascular Risk in Primary Aldosteronism.
    Adolf C; Schneider H; Heinrich DA; Handgriff L; Reincke M
    Horm Metab Res; 2020 Jun; 52(6):386-393. PubMed ID: 32252107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypertension caused by primary hyperaldosteronism: increased heart damage and cardiovascular risk.
    Abad-Cardiel M; Alvarez-Álvarez B; Luque-Fernandez L; Fernández C; Fernández-Cruz A; Martell-Claros N
    Rev Esp Cardiol (Engl Ed); 2013 Jan; 66(1):47-52. PubMed ID: 23153688
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of primary aldosteronism among Asian hypertensive patients in Singapore.
    Loh KC; Koay ES; Khaw MC; Emmanuel SC; Young WF
    J Clin Endocrinol Metab; 2000 Aug; 85(8):2854-9. PubMed ID: 10946893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cardiovascular consequences of hyperaldosteronism.
    Rossi GP; Seccia TM; Maiolino G; Cesari M
    Ann Endocrinol (Paris); 2021 Jun; 82(3-4):174-178. PubMed ID: 32192789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of Cardiovascular Disease and Its Risk Factors in Primary Aldosteronism: A Multicenter Study in Japan.
    Ohno Y; Sone M; Inagaki N; Yamasaki T; Ogawa O; Takeda Y; Kurihara I; Itoh H; Umakoshi H; Tsuiki M; Ichijo T; Katabami T; Tanaka Y; Wada N; Shibayama Y; Yoshimoto T; Ogawa Y; Kawashima J; Takahashi K; Fujita M; Watanabe M; Matsuda Y; Kobayashi H; Shibata H; Kamemura K; Otsuki M; Fujii Y; Yamamoto K; Ogo A; Okamura S; Miyauchi S; Fukuoka T; Izawa S; Yoneda T; Hashimoto S; Yanase T; Suzuki T; Kawamura T; Tabara Y; Matsuda F; Naruse M; ;
    Hypertension; 2018 Mar; 71(3):530-537. PubMed ID: 29358460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renal cysts and hypokalemia in primary aldosteronism: results of long-term follow-up after treatment.
    Novello M; Catena C; Nadalini E; Colussi GL; Baroselli S; Chiuch A; Lapenna R; Bazzocchi M; Sechi LA
    J Hypertens; 2007 Jul; 25(7):1443-50. PubMed ID: 17563567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary aldosteronism: an update on screening, diagnosis and treatment.
    Rossi GP; Pessina AC; Heagerty AM
    J Hypertens; 2008 Apr; 26(4):613-21. PubMed ID: 18327065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primary aldosteronism in the primary care setting.
    Buffolo F; Monticone S; Tetti M; Mulatero P
    Curr Opin Endocrinol Diabetes Obes; 2018 Jun; 25(3):155-159. PubMed ID: 29629943
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular and renal damage in primary aldosteronism: outcomes after treatment.
    Sechi LA; Colussi G; Di Fabio A; Catena C
    Am J Hypertens; 2010 Dec; 23(12):1253-60. PubMed ID: 20706195
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary aldosteronism: cardiovascular, renal and metabolic implications.
    Rossi GP; Sechi LA; Giacchetti G; Ronconi V; Strazzullo P; Funder JW
    Trends Endocrinol Metab; 2008 Apr; 19(3):88-90. PubMed ID: 18314347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aldosterone and cardiovascular disease.
    Gaddam KK; Pimenta E; Husain S; Calhoun DA
    Curr Probl Cardiol; 2009 Feb; 34(2):51-84. PubMed ID: 19135616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary aldosteronism: renaissance of a syndrome.
    Young WF
    Clin Endocrinol (Oxf); 2007 May; 66(5):607-18. PubMed ID: 17492946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis.
    Monticone S; D'Ascenzo F; Moretti C; Williams TA; Veglio F; Gaita F; Mulatero P
    Lancet Diabetes Endocrinol; 2018 Jan; 6(1):41-50. PubMed ID: 29129575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary Aldosteronism: Cardiovascular Outcomes Pre- and Post-treatment.
    Hundemer GL
    Curr Cardiol Rep; 2019 Jul; 21(9):93. PubMed ID: 31352525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary Aldosteronism and Obstructive Sleep Apnea: Is This A Bidirectional Relationship?
    Prejbisz A; Kołodziejczyk-Kruk S; Lenders JWM; Januszewicz A
    Horm Metab Res; 2017 Dec; 49(12):969-976. PubMed ID: 29202496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary aldosteronism and its various clinical scenarios.
    Martell-Claros N; Abad-Cardiel M; Alvarez-Alvarez B; García-Donaire JA; Pérez CF
    J Hypertens; 2015 Jun; 33(6):1226-32. PubMed ID: 25715092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence and characteristics of the metabolic syndrome in primary aldosteronism.
    Fallo F; Veglio F; Bertello C; Sonino N; Della Mea P; Ermani M; Rabbia F; Federspil G; Mulatero P
    J Clin Endocrinol Metab; 2006 Feb; 91(2):454-9. PubMed ID: 16291704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.